Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Leber s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Leber s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Overview | 8 | 1 |
| Pipeline Products for Leber s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Comparative Analysis | 9 | 1 |
| Leber s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Therapeutics under Development by Companies | 10 | 1 |
| Leber s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Leber s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Pipeline Products Glance | 12 | 4 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Unknown Stage Products | 15 | 1 |
| Leber s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Products under Development by Companies | 16 | 1 |
| Leber s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Products under Investigation by Universities/Institutes | 17 | 1 |
| Leber s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Companies Involved in Therapeutics Development | 18 | 7 |
| Alkeus Pharmaceuticals, Inc. | 18 | 1 |
| Biovista Inc. | 19 | 1 |
| GenSight Biologics S.A. | 20 | 1 |
| Ixchel Pharma, LLC | 21 | 1 |
| Khondrion BV | 22 | 1 |
| Spark Therapeutics, Inc. | 23 | 1 |
| Stealth BioTherapeutics Inc. | 24 | 1 |
| Leber s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Therapeutics Assessment | 25 | 9 |
| Assessment by Monotherapy Products | 25 | 1 |
| Assessment by Target | 26 | 2 |
| Assessment by Mechanism of Action | 28 | 2 |
| Assessment by Route of Administration | 30 | 2 |
| Assessment by Molecule Type | 32 | 2 |
| Drug Profiles | 34 | 18 |
| BVA-202 Drug Profile | 34 | 1 |
| BVA-203 Drug Profile | 35 | 1 |
| Drug for Lebers Hereditary Optic Neuropathy Drug Profile | 36 | 1 |
| elamipretide Drug Profile | 37 | 6 |
| Gene Therapy to Activate ND4 for Leber's Hereditary Optic Neuropathy Drug Profile | 43 | 1 |
| GS-010 Drug Profile | 44 | 2 |
| GS-011 Drug Profile | 46 | 1 |
| IXC-201 Drug Profile | 47 | 1 |
| IXC-203 Drug Profile | 48 | 1 |
| KH-176 Drug Profile | 49 | 2 |
| SPK-LHON Drug Profile | 51 | 1 |
| Leber s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Dormant Projects | 52 | 1 |
| Leber s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Product Development Milestones | 53 | 6 |
| Featured News &Press Releases | 53 | 1 |
| Sep 08, 2016: GenSight Biologics Receives Approval to Include Teenage Patients in RESCUE and REVERSE Phase III Trials with GS010 in Leber s Hereditary Optic Neuropathy | 53 | 1 |
| Jun 08, 2016: GenSight Biologics Announces Additional Promising Results of Its Phase I/II Study with GS010 for the Treatment of Leber s Hereditary Optic Neuropathy (LHON) | 54 | 1 |
| Jun 01, 2016: Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Leber's Hereditary Optic Neuropathy | 55 | 1 |
| Feb 29, 2016: GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber s Hereditary Optic Neuropathy | 55 | 2 |
| Sep 10, 2015: GenSight Biologics Receives IND Acceptance from FDA to Enter Phase III with GS010 | 57 | 1 |
| Dec 15, 2014: New CMO joins Khondrion | 57 | 2 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |